Welcome to our dedicated page for Lava Therapeutics Bv news (Ticker: LVTX), a resource for investors and traders seeking the latest updates and insights on Lava Therapeutics Bv stock.
LAVA Therapeutics Bv (LVTX) is a clinical-stage biotechnology pioneer developing targeted cancer therapies through its proprietary Gammabody® platform. This page serves as the definitive source for verified company updates, providing stakeholders with essential information about therapeutic advancements and strategic developments.
Investors and researchers will find timely updates on clinical trial progress, regulatory milestones, and strategic partnerships in immuno-oncology. Our curated collection includes press releases detailing bispecific T cell engager developments, preclinical research breakthroughs, and corporate collaborations that shape the company's trajectory.
All content undergoes rigorous verification to ensure accuracy and relevance. Regular updates cover key areas including Phase I/II trial results, platform technology enhancements, and market positioning updates. Bookmark this page for direct access to primary source materials that inform investment decisions and industry analysis.
LAVA Therapeutics, a clinical-stage immuno-oncology company, will participate in the Jefferies Global Healthcare Conference. Stephen Hurly, President and CEO, will represent the company in a fireside chat on June 5, 2024, at 8:00 a.m. ET. The discussion will be available via webcast on the company's investor relations website. The webcast replay will be archived for 90 days following the event. LAVA focuses on developing its proprietary Gammabody® platform of bispecific gamma-delta T cell engagers.
LAVA Therapeutics provided updates and financial results for Q1 2024. Key developments include the ongoing Phase 1/2a trial of LAVA-1207 for prostate cancer, with a pembrolizumab combination expected in Q2 2024. LAVA received a $7 million milestone payment from Pfizer for PF-08046052 in Phase 1 trials. LAVA-1266 is on track for Q2 2024 IND submission. Financially, LAVA reported $7 million in revenue for Q1 2024, up from $1.2 million in Q1 2023, with cash reserves at $94.6 million, providing a runway into 2026. The net loss improved to $0.5 million from $13.9 million in Q1 2023, mainly due to reduced R&D and administrative expenses.
LAVA Therapeutics N.V. (NASDAQ: LVTX) will participate in the Citizens JMP Life Sciences Conference where Stephen Hurly, President and CEO, will join a fireside chat. The event will take place on May 13, 2024, at 10:00 a.m. ET. The webcast can be accessed on the investor relations section of the LAVA Therapeutics website.
FAQ
What is the current stock price of Lava Therapeutics Bv (LVTX)?
What is the market cap of Lava Therapeutics Bv (LVTX)?
